Výsledky vyhledávání - "Robert L. Krigel"

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer

Autor: John H. Glick, Joan H. Schiller, William Tester, Philip Bonomi, Robert F. Asbury, Robert L. Krigel, John M. Kirkwood, Kyung Mann Kim, Ronald H. Blum

Publikováno v: Lung Cancer. 25:199-206

Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f4834b9afcda07a862eea406bc1b5f1
https://doi.org/10.1016/s0169-5002(99)00054-9

Zobrazit plný text záznamu

The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status

Autor: Robert L. Krigel, Brian P. O'Neill, John D. Earle, Chiao Hua Wang, Joseph P. Colgan, William J. McGinnis, Judith R. O'Fallon, Loren D. Brown

Publikováno v: Neuro-Oncology. 1:196-203

Per protocol, patients with primary CNS non-Hodgkin's lymphoma in an intergroup phase II trial conducted by the North Central Cancer Treatment Group and the Eastern Cooperative Oncology Group had their cognitive functions measured using the Folstein

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::803a315a3062324f20478b6ab393598a
https://doi.org/10.1093/neuonc/1.3.196

Zobrazit plný text záznamu

Primary central nervous system non-hodgkin's lymphoma: Survival advantages with combined initial therapy?

Autor: Robert L. Krigel, John D. Earle, Judith R. O'Fallon, Loren D. Brown, Brian P. O'Neill, Joseph P. Colgan

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 33:663-673

Purpose: Results of multiple radiation, chemotherapy, and combined treatment trials have shown that the fate of primary central nervous system lymphoma (PCNSL) patients is very different from that of patients with similarly treated systemic IE non-Ho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87604937375e8a9461c07b77bfb2959c
https://doi.org/10.1016/0360-3016(95)00207-f

Zobrazit plný text záznamu

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

Autor: Samuel Litwin, R Scher, P Watts, Robert L. Krigel, Kenneth D. Tew, Richard N. Greenberg, S Fox, Robert L. Comis, Gary R. Hudes, L Speicher

Publikováno v: Journal of Clinical Oncology. 10:1754-1761

PURPOSE Estramustine phosphate (EMP) and vinblastine are two microtubule inhibitors with distinct molecular targets and at least additive antimicrotubule effects in vitro. Their modest single-agent activities in hormone-refractory prostate cancer, no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::607d3f2652f7c314cf046a5e48a59d1e
https://doi.org/10.1200/jco.1992.10.11.1754

Zobrazit plný text záznamu

Interferon-γ Induced by Administration of Recombinant Interleukin-2 to Patients with Cancer

Autor: Michael W. Konrad, Eric C. Groves, Alfred Rudolph, Edward C. Bradley, Gary Goodman, Susanne K. DeWitt, Robert L. Krigel, Evan M. Hersh

Publikováno v: Journal of Immunotherapy. 12:55-63

The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-gamma levels of 1 to 500 U/ml. After a lag of 1 h, interferon-gamma rises to a m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02c37a1a9c4191ba6a365c3538fb3bb
https://doi.org/10.1097/00002371-199207000-00007

Zobrazit plný text záznamu

Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

Autor: Patrick J. Loehrer, Paul L. Schaefer, Barbara A. Murphy, Robert L. Krigel, Marc S. Ernstoff, Jason P. Fine, Janice P. Dutcher

Publikováno v: Medical oncology (Northwood, London, England). 20(3)

Introduction: Standard therapy for recurrent or metastatic renal carcinoma includes the biologic response modifiers interferon-alpha (IFN-α) and interleukin-2 (IL-2). The response rate for both agents is modest and toxicity is significant. New agent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2331be60b2fbda18a7982645f0083d7
https://pubmed.ncbi.nlm.nih.gov/14514977

Zobrazit plný text záznamu

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma

Autor: Robert L. Krigel, Donald L. Trump, Marc S. Ernstoff, Robert S. Witte, Jules E. Harris, Martin M. Oken, Traci Leong, Douglass C. Tormey

Publikováno v: Investigational new drugs. 13(3)

Biologic response modifiers have activity in renal cell carcinoma. The combination of interleukin-2 (IL-2) and beta-interferon (B-IFN) is synergistic in vitro. This trial was initiated to determine the efficacy of IL-2 alone and with B-IFN in advance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c315d03d4078459f3373b4fbe3128780
https://pubmed.ncbi.nlm.nih.gov/8729953

Zobrazit plný text záznamu

Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer

Autor: C S Palackdharry, Naomi B. Haas, D Kilpatrick, Corey J. Langer, Robert L. Comis, Robert L. Krigel, K Padavic

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(6)

PURPOSE A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF). PATIENTS AND METHODS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10c0d43815494984331a35dd519823b7
https://pubmed.ncbi.nlm.nih.gov/8201386

Zobrazit plný text záznamu

Hoarseness; a unique clinical presentation for renal cell carcinoma

Autor: Robert L. Krigel, Jeffery T Cooper, R. Melvyn Richter, Howard Kessler, Richard E. Greenberg, Robert O. Petersen

Publikováno v: Urology. 40(2)

The first reported case of an isolated metastasis to the larynx from a regionally localized renal cell carcinoma presenting clinically as hoarseness is discussed. Aggressive management and outcome are presented.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20fec2f94c544365c87b5948c8ea17bd
https://pubmed.ncbi.nlm.nih.gov/1502755

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání